`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`‐‐‐‐‐BEGIN PRIVACY‐ENHANCED MESSAGE‐‐‐‐‐
`Proc‐Type: 2001,MIC‐CLEAR
`Originator‐Name: keymaster@town.hall.org
`Originator‐Key‐Asymmetric:
` MFkwCgYEVQgBAQICAgADSwAwSAJBALeWW4xDV4i7+b6+UyPn5RtObb1cJ7VkACDq
` pKb9/DClgTKIm08lCfoilvi9Wl4SODbR1+1waHhiGmeZO8OdgLUCAwEAAQ==
`MIC‐Info: RSA‐MD5,RSA,
` bWazcY4ZnZdrqir009lXFtDuLuowzJJecXjeyjqGgKWpAlGft4WKRMujvpdfW8LF
` LbiPlnFXm8N6ydKhby2qRw==
`
`<IMS‐DOCUMENT>0000892569‐94‐000085.txt : 19940331
`<IMS‐HEADER>0000892569‐94‐000085.hdr.sgml : 19940331
`ACCESSION NUMBER:
`
`0000892569‐94‐000085
`CONFORMED SUBMISSION TYPE:
`10‐K
`PUBLIC DOCUMENT COUNT:
`8
`CONFORMED PERIOD OF REPORT:
`19931231
`FILED AS OF DATE:
`
`19940328
`
`FILER:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`COMPANY DATA:
`
`
`COMPANY CONFORMED NAME:
`
`
`CENTRAL INDEX KEY:
`
`
`STANDARD INDUSTRIAL CLASSIFICATION:
`
`IRS NUMBER:
`
`
`
`
`STATE OF INCORPORATION:
`
`
`FISCAL YEAR END:
`
`
`
`ALLERGAN INC
`0000850693
`2834
`951622442
`DE
`1231
`
`FILING VALUES:
`
`
`FORM TYPE:
`
`
`SEC ACT:
`
`SEC FILE NUMBER:
`
`FILM NUMBER:
`
`
`10‐K
`34
`001‐10269
`94518114
`
`2525 DUPONT DR
`IRVINE
`CA
`92715
`7147524500
`
`
`BUSINESS ADDRESS:
`
`
`
`STREET 1:
`
`
`
`CITY:
`
`
`
`STATE:
`
`
`
`ZIP:
`
`
`
`BUSINESS PHONE:
`
`</IMS‐HEADER>
`<DOCUMENT>
`<TYPE>10‐K
`<SEQUENCE>1
`<DESCRIPTION>FORM 10‐K
`<TEXT>
`
`<PAGE> 1
`
` FORM 10‐K
` SECURITIES AND EXCHANGE COMMISSION
` Washington, D.C. 20549
`
`ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
` 1934
` FOR THE FISCAL YEAR ENDED DECEMBER 31, 1993
`
` COMMISSION FILE NO.1‐10269
`
` ALLERGAN, INC.
` (Exact name of Registrant as Specified in its Charter)
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`1/217
`
`MYLAN - EXHIBIT 1068
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc. - IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`
`
`6/20/2017
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`<TABLE>
`<S> <C>
` DELAWARE 95‐1622442
` (State of Incorporation) (I.R.S. Employer
` Identification No.)
`
` 2525 DUPONT DRIVE
` IRVINE, CALIFORNIA 92715‐1599
` (Address of principal executive offices) (Zip Code)
`</TABLE>
`
` Registrant's telephone number: (714) 752‐4500
`
` Securities registered pursuant to Section 12(b) of the Act:
`
`<TABLE>
` <S> <C>
` Title of each class Name of each exchange on which each
`class registered
`
` Common Stock, $0.01 par value New York Stock Exchange
` Preferred Share Purchase Rights
`</TABLE>
`
` Securities registered pursuant to Section 12(g) of the Act:
` NONE
`
` Indicate by check mark whether the registrant (1) has filed all
`reports required to be filed by Section 13 or 15(d) of the Securities Exchange
`Act of 1934 during the preceding 12 months, and (2) has been subject to such
`filing requirements for the past 90 days.
` Yes E No____
`
` The aggregate market value of the registrant's voting stock held by
`non‐affiliates was approximately $1,400,000,000 on February 28, 1994, based
`upon the closing price on the New York Stock Exchange on such date.
`
` Common Stock outstanding as of February 28, 1994 ‐ 63,904,229 shares
`
` Indicate by check mark if disclosure of delinquent filers pursuant to
`Item 405 of Regulation S‐K is not contained herein, and will not be contained,
`to the best of registrant's knowledge, in definitive proxy or information
`statements incorporated by reference in Part III of this Form 10‐K or any
`amendement to this Form 10‐K. [ ]
`
` DOCUMENTS INCORPORATED BY REFERENCE
`
` Parts I, II and IV incorporate certain information by reference from
`the registrant's Annual Report to Stockholders for the fiscal year ended
`December 31, 1993. With the exception of the sections of the Annual Report
`specifically incorporated by reference herein, the Annual Report is not deemed
`filed as part of this Report on Form 10‐K.
` Part III incorporates certain information by reference from the
`registrant's definitive proxy statement for the annual meeting of stockholders
`to be held on April 19, 1994, which proxy statement will be filed no later than
`120 days after the close of the registrant's fiscal year ended December 31,
`1993.
`<PAGE> 2
` TABLE OF CONTENTS
`
`<TABLE>
`<CAPTION>
`PART I PAGE
`<S> <C>
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`2/217
`
`
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`6/20/2017
`Item 1. Business................................................................. 1
`Item 2. Properties............................................................... 7
`Item 3. Legal Proceedings........................................................ 8
`Item 4. Submission of Matters to a Vote of Security Holders...................... 9
`Item I‐A. Executive Officers of Allergan, Inc. .................................... 9
`
`PART II
`
`Item 5. Market for Registrant's Common Equity and Related
` Stockholder Matters......................................................... 12
`Item 6. Selected Financial Data..................................................... 12
`Item 7. Management's Discussion and Analysis of Financial
` Condition and Results of Operations......................................... 12
`Item 8. Financial Statements and Supplementary Data................................. 12
`Item 9. Changes in and Disagreements with Accountants on
` Accounting and Financial Disclosure......................................... 12
`
`PART III
`
`Item 10. Directors and Executive Officers of Allergan, Inc. ......................... 13
`Item 11. Executive Compensation...................................................... 13
`Item 12. Security Ownership of Certain Beneficial Owners and
` Management.................................................................. 13
`Item 13. Certain Relationships and Related Transactions.............................. 13
`
`PART IV
`
`Item 14. Exhibits, Financial Statement Schedules and Reports
` on Form 8‐K................................................................. 14
`
`SIGNATURES............................................................................... 15
`INDEX OF EXHIBITS........................................................................ 19
`INDEPENDENT AUDITORS' REPORTS ON SCHEDULES............................................... 20
`SCHEDULES................................................................................ S‐1
`EXHIBITS.........................................................................(Attached to this
` Report on Form 10‐
`K)
`</TABLE>
`<PAGE> 3
`
` PART I
`
`ITEM 1. BUSINESS
`
`GENERAL DEVELOPMENT OF BUSINESS
`
` Allergan, Inc. ("Allergan" or the "Company") is a global provider of
`specialty therapeutic products principally in the areas of eye and skin care.
`Its worldwide consolidated revenues are generated by prescription and
`non‐prescription pharmaceutical products in the areas of ophthalmology and
`dermatology, intraocular lenses (IOLs) and other ophthalmic surgical products,
`and contact lens care products.
`
` Allergan was incorporated in California in 1948 and reincorporated in
`Delaware in 1977. In 1980, the Company was acquired by SmithKline Beckman
`Corporation (then known as "SmithKline Corporation" and herein "SmithKline").
`The Company operated as a wholly‐ owned subsidiary of SmithKline from 1980
`until July 27, 1989 when Allergan again became a stand‐alone public company
`through a spin‐ off distribution by SmithKline.
`
` During the fourth quarter of 1991, the Company divested its computer‐based
`ophthalmic diagnostic instrument business, Allergan Humphrey. In November
`1992, the Company sold its contact lens business in North and South America.
`In August 1993, the Company sold its contact lens business outside of the
`Americas.
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`3/217
`
`
`
`6/20/2017
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`ALLERGAN BUSINESSES
`
` The following table sets forth, for the periods indicated, the net sales
`from continuing operations for each of the Company's specialty therapeutics
`businesses:
`
`<TABLE>
`<CAPTION>
` ____ Year Ended December 31_____
` ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐
` 1993 1992 1991
` ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐
` (in millions)
` <S> <C> <C> <C>
` Specialty Pharmaceuticals
` Eye Care $386.2 $359.2 $317.7
` Skin Care 32.4 37.3 36.5
` ‐‐‐‐‐‐‐‐‐ ‐‐‐‐‐‐‐‐ ‐‐‐‐‐‐‐‐
` 418.6 396.5 354.2
`
` Surgical 115.3 111.8 108.2
` Optical Lens Care 325.0 322.4 299.3
` ‐‐‐‐‐ ‐‐‐‐‐ ‐‐‐‐‐
`
` TOTAL $858.9 $830.7 $761.7
` ====== ====== ======
`
` Domestic
` 47.5% 47.9% 50.4%
` International 52.5% 52.1% 49.6%
`
`
`</TABLE>
`
` The foregoing table does not include sales of discontinued operations.
`See Note 10 of Notes to Consolidated Financial Statements on page 46 of the
`1993 Annual Report for further information concerning foreign and domestic
`operations.
`
`Specialty Pharmaceuticals
`
` Allergan develops, manufactures and markets a broad range of prescription
`ophthalmic products designed to treat diseases and disorders of the eye,
`including glaucoma, inflammation,
`
` 1
`
`<PAGE> 4
`infection, allergy and ophthalmic muscle disorders. In addition, the specialty
`over‐the‐counter ("OTC") product line consists of
`products designed to treat ocular surface disease, including artificial tears
`and ocular decongestants.
`
` The largest segment of the market for ophthalmic prescription drugs is for
`the treatment of glaucoma, a sight‐threatening disease characterized by
`elevated intraocular pressure. For initial treatment of glaucoma, Allergan
`sells BETAGAN(R) ophthalmic solution, a beta adrenergic blocking agent;
`BETAGAN(R) is Allergan's largest selling pharmaceutical product. PROPINE(R)
`ophthalmic solution is the product which is used alone or in combination with
`other drugs when initial drug therapy for glaucoma becomes inadequate. Patent
`protection for both products expired in the United States in 1991. Although
`the Company has not experienced generic competition to date, such competition
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`4/217
`
`
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`6/20/2017
`is expected to develop in 1994. In 1993, Allergan entered into an agreement
`with Schein Pharmaceutical, Inc. whereby Schein will market generic versions of
`certain Allergan products that are off‐ patent in the U.S.; in March 1994,
`Schein began marketing a generic version of BETAGAN(R) . Also in March 1994,
`Bausch & Lomb announced that it had obtained approval from the United States
`Food and Drug Administration ("FDA") to market a generic version of BETAGAN(R)
`.
`
` Allergan holds a major share of the U.S. market for ophthalmic steroids.
`The Company's PRED FORTE(R) product is widely prescribed to fight ocular
`inflammation.
`
` In 1993, Allergan entered into a strategic alliance with Fisons
`Corporation to co‐promote certain ophthalmic pharmaceuticals in the United
`States. The alliance currently involves Allergan's ACULAR(R) 1 ophthalmic
`solution for the relief of itch associated with seasonal allergic
`conjunctivitis. Later, under the terms of the alliance, co‐promotion is
`planned to expand to include Fisons' OPTICROM(R) 2 ophthalmic solution and
`nedocromil sodium ophthalmic solution.
`
` Allergan's specialty pharmaceuticals include BOTOX(R) (Botulinum Toxin
`Type A) purified neurotoxin complex for the treatment of certain neuromuscular
`disorders which are characterized by involuntary muscle contractions or spasms.
`BOTOX(R) purified neurotoxin complex is being marketed in the United States,
`Canada, Germany, France, Italy, New Zealand and a number of other countries for
`the treatment of blepharospasm (the uncontrollable abnormal contraction of the
`eyelid muscles which can force the eye closed) and strabismus (misalignment of
`the eyes) in people 12 years of age and over. In March 1991, an application
`was filed with United States FDA for approval of a nonophthalmic claim for an
`indication related to a neck and shoulder neuromuscular disorder known as
`cervical dystonia (torticollis). Allergan has been asked to provide
`supplemental clinical data to support the torticollis filing.
`
` Building upon its strength in marketing to medical specialties and taking
`advantage of synergies in research and development, Allergan's skin care
`division (known as Allergan Herbert) develops, manufactures and markets a line
`of therapeutic skin care products primarily to dermatologists in the United
`States. Its product line includes GRIS‐PEG(R) tablets, a systemic anti‐fungal
`product, ELIMITE(R) cream for the treatment of scabies and NAFTIN(R) , a
`topical anti‐fungal gel and cream.
`
`___________________________________
`(1)ACULAR(R) is a registered trademark, which is llicensed from Syntex (U.S.A.)
` Inc.
`
`(2)OPTICROM(R) is a registered trademark of Fisons Corporation.
`
` 2
`
`<PAGE> 5
`Surgical
`
` Allergan's surgical division (known as Allergan Medical Optics or AMO)
`develops, manufactures and markets intraocular lenses (IOLs), surgically
`related pharmaceuticals, phacoemulsification equipment and other ophthalmic
`surgical products.
`
` The largest segment of the surgical market is for the treatment of
`cataracts. IOLs are used to replace the natural lens of a cataract patient
`when it has become clouded. To meet the wide range of IOL products demanded by
`the market, Allergan currently offers a variety of models, including rigid
`multi‐piece and single‐piece and small incision designs. Lenses for small
`incision surgery include the AMO(R) PHACOFLEX(R) small incision IOL,
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`5/217
`
`
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`6/20/2017
`introduced in 1989, and the AMO(R) Foldable PHACOFLEX(R) II SI‐30NB(TM) small
`incision IOL, introduced in April 1993. Small incision IOLs continue to grow
`in popularity along with increasing use of phacoemulsification, a method of
`cataract extraction that uses ultrasound waves to break the natural lens into
`small fragments that can be removed through a hollow needle.
`Phacoemulsification requires only a 3 to 4 millimeter incision, compared to
`incisions of up to 12 millimeters for other techniques. In 1993, AMO
`introduced the AMO(R) PRESTIGE(TM), which Allergan believes represents a
`significant technological advance in phacoemulsification equipment.
`
` Sales growth of IOLs in the U.S. has been adversely impacted by price
`erosion resulting from competitive pressures.
`
`Optical
`
` The Company has been in the contact lens care market since 1960. It
`develops, manufactures and markets a broad range of products worldwide for use
`with every available type of contact lens. These products include daily
`cleaners to remove undesirable film and deposits from hard, rigid gas permeable
`and soft contact lenses; enzymatic cleaners to remove protein deposits from the
`surface of contact lenses; and disinfecting solutions to destroy harmful
`microorganisms on the surface of contact lenses. Allergan offers products that
`can be used in each of the three disinfecting systems now available: heat
`systems, cold chemical systems and hydrogen peroxide systems. ULTRACARE(R)
`neutralizer/disinfectant, Allergan's one‐step hydrogen peroxide disinfection
`system, was approved by the FDA in March 1992 for general marketing in the U.S.
`COMPLETE(R) , a one‐bottle "cold chemical" disinfection system for soft contact
`lenses was launched in several countries in the Pan‐Asia and Europe regions
`during 1993. The U.S. filing for marketing approval of COMPLETE(R) was made
`with the FDA in December 1991.
`
` Sales of the Company's proprietary enzymatic cleaners represented 12%, 11%
`and 11% of total Company sales in 1991, 1992 and 1993, respectively, and sales
`of the Company's hydrogen peroxide disinfection systems represented 14%, 13%
`and 14% of total Company sales in 1991, 1992 and 1993, respectively.
`
`EMPLOYEE RELATIONS
`
` At December 31, 1993 the Company employed approximately 4,749 persons
`throughout the world, including approximately 2,185 in the United States. None
`of the Company's U.S.‐based employees are represented by unions. The Company
`considers that its relations with its employees are, in general, very good.
`
` 3
`<PAGE> 6
`
`INTERNATIONAL OPERATIONS
`
` The Company believes that international markets represent a significant
`opportunity for continued growth. Allergan believes that its well‐established
`international market presence provides it with a competitive advantage,
`enabling the Company to maximize the return on its investment in research,
`product development and manufacturing.
`
` Allergan established its first foreign subsidiary in 1964 and currently
`sells products in approximately 100 countries. Marketing activities are
`coordinated on a worldwide basis and resident management teams provide
`leadership and infrastructure for customer focused rapid introduction of new
`products in their local markets.
`
` In Japan, the second largest eye care market in the world, certain of
`Allergan's eye care pharmaceutical products are licensed to Santen
`Pharmaceuticals (the largest eye care pharmaceutical manufacturer in Japan),
`and Allergan's contact lens care products are sold through a joint venture
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`6/217
`
`
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`6/20/2017
`between Santen and Allergan. IOLs and other eye care surgical products are
`sold directly in Japan.
`
`SALES AND MARKETING
`
` Allergan maintains global marketing and regional sales organizations.
`Supplementing the sales efforts and promotional activities aimed at eye and
`skin care professionals, as well as neurologists outside the U.S., who use,
`prescribe and recommend its products, Allergan has been shifting its resources
`increasingly toward managed care providers. In addition, Allergan advertises
`in professional journals and has an extensive direct mail program of
`descriptive product literature and scientific information to specialists in the
`ophthalmic and dermatological fields. The Company's specialty therapeutic
`products are sold to drug wholesalers, independent and chain drug stores,
`commercial optical chains, mass merchandisers, food stores, hospitals,
`ambulatory surgery centers (ASCs) and medical practitioners, including
`neurologists. At December 31, 1993 the Company employed approximately 800
`sales representatives throughout the world.
`
`RESEARCH AND DEVELOPMENT
`
` The Company's global research and development efforts focus on eye care,
`skin care and neuromuscular products that are safe, effective, convenient and
`have an economic benefit. The Company's own research and development
`activities are supplemented by a commitment to identifying and obtaining new
`technologies through in‐licensing, joint ventures and acquisition efforts
`including the establishment of research relationships with academic
`institutions and individual researchers.
`
` Research and development efforts for specialty pharmaceuticals focus
`primarily on new therapeutic products for glaucoma, inflammation, dry eye,
`allergy, dystonias and other neuromuscular disorders, and new anti‐infective
`pharmaceuticals for eye care, acne, inflammation and psoriasis. During the
`first quarter of 1993, Allergan began Phase III clinical trials with its
`proprietary topical retinoid tarazotene (AGN190168) for both acne and
`psoriasis. The results of these trials are expected to be available beginning
`in the middle of 1994.
`
` Research and development activities for the surgical division concentrate
`on improved cataract surgical systems, implantation instruments and methods,
`and new IOL materials and designs, including the AMO(R) ARRAY(R) multifocal
`IOL, designed to allow patients to see well over a range of distances.
`
` 4
`<PAGE> 7
`
` Research and development in the contact lens care product area is aimed at
`care systems which, without sacrificing efficacy or antimicrobial activity,
`will be more convenient for patients to use and thus lead to a higher rate of
`compliance with recommended lens care procedures. Improved compliance can
`enhance safety and extend the time a patient will be a contact lens wearer.
`The Company believes that continued development and commercialization of
`disinfection systems that are both easy‐to‐use and efficacious will be
`important for the future success of this part of the Company's business.
`
` During 1992, the Company entered into a joint venture with Ligand
`Pharmaceuticals Corporation to combine Ligand's knowledge of intracellular
`receptor technology with the Company's experience in receptor‐selective
`retinoids for topical use. The joint venture filed an Investigational New Drug
`Application with the FDA in November 1993 for the use of 9‐cis Retinoic acid
`(LGD1057) to be given orally for cancer therapy. In 1993, the Company signed
`an agreement with Sandoz Pharmaceuticals Corporation to develop, manufacture
`and market cyclosporine A for all topical ophthalmic uses. In addition, the
`Company has entered into a number of collaborative arrangements with academic
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`7/217
`
`
`
`6/20/2017
`institutions.
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
` The continuing introduction of new products supplied by the Company's
`research and development efforts and in‐licensing opportunities is critical to
`the success of the Company. Delays or failures in one or more significant
`research projects could have a material adverse impact on the future operations
`of the Company.
`
` At December 31, 1993 there were an aggregate of approximately 630 people
`involved in the Company's research and development efforts. The Company's
`research and development expenditures associated with continuing operations for
`1991, 1992 and 1993 were $70.4 million, $89.5 million and $102.5 million
`respectively.
`
`COMPETITION
`
` Allergan faces strong competition in all of its markets. Numerous
`companies are engaged in the development, manufacture and marketing of health
`care products competitive with those manufactured by Allergan, although these
`companies do not necessarily compete in all of Allergan's product lines. Major
`eye care competitors include Merck, Alcon Laboratories (a subsidiary of
`Nestle), Bausch & Lomb, Ciba Vision Corp. (a subsidiary of Ciba‐Geigy), IOLab
`(a subsidiary of Johnson & Johnson), Pharmacia Ophthalmics (a subsidiary of
`Kabi Pharmacia), Sola/Barnes‐Hind (a subsidary of Pilkington plc) and
`Wessley‐Jessen, Inc. (a subsidiary of Schering‐ Plough Corporation). These
`competitors have equivalent or greater resources than Allergan. The Company's
`skin care business competes against a number of companies which have greater
`resources than Allergan. In marketing its products to health care
`professionals, the Company competes primarily on the basis of product
`technology, service and price.
`
`GOVERNMENT REGULATION
`
` Drugs, biologics and medical devices, including IOLs and contact lens care
`products, are subject to regulation by the FDA, state agencies and, in varying
`degrees, by foreign health agencies. FDA regulation of many of the Company's
`products generally requires extensive testing of new products and filing
`applications for approval by the FDA prior to sale in the United States. The
`FDA reviews these applications and determines whether the product is safe and
`effective. The process of developing data to support a pre‐market application
`and FDA review can be costly and take many years to complete.
`
` Manufacturers of drugs, medical devices and biologics are operating in a
`more rigorous regulatory environment than has been the case in previous years.
`Several legislative and administrative measures to strengthen government
`regulation of medical devices and drugs have
`
` 5
`<PAGE> 8
`
`recently been implemented in the United States, such as the Safe Medical
`Devices Act of 1990, which among other things, increased reporting requirements
`of adverse events associated with medical devices, and the Prescription Drug
`Law Fee Act of 1992, which requires payment of substantial fees to the FDA for
`new drug applications. Other measures are pending or have been proposed. In
`addition, there has been increased scrutiny of drug and device manufacturers by
`the FDA as a result of a scandal in the generic drug industry and controversies
`surrounding the safety of certain medical devices. While the Company is not
`primarily involved in these areas of business, the impact of increased FDA
`scrutiny is felt by all companies in the drug and device industries. Moreover,
`in Europe and other major Allergan markets, the regulation of drugs and medical
`devices is likewise increasing. The Company is working to ensure that its
`operations remain in compliance with FDA and other regulatory requirements.
`
` The total cost of providing health care services has been and will
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`8/217
`
`
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`6/20/2017
`continue to be subject to review by governmental agencies and legislative
`bodies in the major world markets, including the United States, which are faced
`with significant pressure to lower health care costs. Prices for some of the
`Company's products, specifically IOLs and pharmaceutical products, accounting
`for approximately 60% of the Company's 1993 sales, are expected to come under
`increased pressure as governments and managed care providers generally increase
`their efforts to contain health care costs.
`
` In the United States, a significant percentage of the patients who receive
`the Company's IOLs are covered by the federal Medicare program. When a
`cataract extraction with IOL implantation is performed in an ambulatory surgery
`center ("ASC"), Medicare provides the ASC with a fixed $150 allowance to cover
`the cost of the IOL. When the procedure is performed in a hospital outpatient
`department, the hospital's reimbursement is determined using a complex formula
`that blends the hospital's costs with the $150 allowance paid to ASCs. In
`November 1990, the U.S. Health Care Financing Administration (HCFA) issued
`proposed regulations under which Medicare would not recognize hospitals'
`expenditures for IOLs implanted during outpatient cataract surgery to the
`extent that those expenditures exceed the ASC allowance. The Company cannot
`predict whether HCFA will promulgate a final regulation imposing this
`limitation.
`
` The cost of prescription drugs is receiving substantial attention in the
`United States Congress. Legislation enacted in 1990, and amended and
`strengthened in 1992, requires pharmaceutical manufacturers to rebate to the
`government a portion of their revenues from drugs furnished to Medicaid
`patients. In 1992, legislation was enacted that extends these requirements to
`covered outpatient pharmaceuticals, and also mandates a reduction in
`pharmaceutical prices charged to certain federally‐funded facilities as well as
`to certain hospitals serving a disproportionate share of low‐income patients.
`A provision of the Omnibus Budget Reconciliation Act of 1993 limits tax
`benefits currently realized by U.S. manufacturers as a result of the
`manufacture of certain products in Puerto Rico, beginning in 1994. It is
`likely that Congressional attention will continue to focus on the costs of
`drugs generally, and particularly on increases in drug prices in excess of the
`rate of inflation, given the current government initiatives pertaining to the
`overall reform of the U.S. health care system, and those specifically directed
`at lowering total costs. The Clinton Administration's health reform bill would
`provide all Medicare beneficiaries with a comprehensive drug benefit; however,
`manufacturers would be required to pay a "rebate" to the government based on
`the volume of a manufacturer's products sold to Medicare beneficiaries. The
`Company cannot predict the likelihood of passage of these or other similar or
`related bills.
`
` Congress also devoted significant attention in 1992 and in preceding years
`to proposing amendments to the Orphan Drug Act. Under one proposal, once
`cumulative sales of an orphan drug exceed a designated dollar amount the FDA
`would be authorized to approve competitors' marketing applications. The
`Company currently markets one orphan drug product, BOTOX (Botulinum Toxin Type
`A) purified neurotoxin complex.
`
` 6
`<PAGE> 9
` The Company cannot predict what effect these measures would have if they
`were ultimately enacted into law. Nor can it predict whether or in what form
`health care legislation being formulated by the new Administration will be
`passed. However, in general, the adoption of such measures can be expected to
`have an adverse impact on the Company's business.
`
`PATENTS, TRADEMARKS AND LICENSES
`
` Allergan owns or is licensed under numerous patents relating to its
`products, product uses and manufacturing processes. It now has numerous
`patents issued in the United States and corresponding foreign patents issued in
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`
`9/217
`
`
`
`https://www.sec.gov/Archives/edgar/data/850693/000089256994000085.txt
`6/20/2017
`the major countries in which it does business. Allergan believes that its
`patents and lice